Associated Papers
In-silico identification and functional analysis of high-risk oncogenic nsSNPs in the human SDHB gene and their implications for cancer susceptibility.
Siddiqui AJ et al.
3 Biotech, 2025
Succinate dehydrogenase variants in paraganglioma: why are B subunit variants 'bad'?
Gruber LM et al.
Endocrine Oncology (bristol, England), 2023
International initiative for a curated SDHB variant database improving the diagnosis of hereditary paraganglioma and pheochromocytoma.
Ben Aim L et al.
Journal of Medical Genetics, 2022
Quantifying evidence toward pathogenicity for rare phenotypes: The case of succinate dehydrogenase genes, SDHB and SDHD.
Garrett A et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2022
Surveillance of succinate dehydrogenase gene mutation carriers: Insights from a nationwide cohort.
Martins RG et al.
Clinical Endocrinology, 2020
SDHx-related pheochromocytoma/paraganglioma - genetic, clinical, and treatment outcomes in a series of 30 patients from a single center.
Donato S et al.
Endocrine, 2019
Analysis of SDHAF3 in familial and sporadic pheochromocytoma and paraganglioma.
Dwight T et al.
Bmc Cancer, 2017
SDHB-Deficient Cancers: The Role of Mutations That Impair Iron Sulfur Cluster Delivery.
Saxena N et al.
Journal of the National Cancer Institute, 2016
Structural and functional consequences of succinate dehydrogenase subunit B mutations.
Kim E et al.
Endocrine-related Cancer, 2015
Corrigendum: inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors.
Xiao M et al.
Genes & Development, 2015
A founder SDHB mutation in Portuguese paraganglioma patients.
Martins RG et al.
Endocrine-related Cancer, 2013
Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function.
Yang C et al.
Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology, 2012
Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors.
Xiao M et al.
Genes & Development, 2012
The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas.
Burnichon N et al.
The Journal of Clinical Endocrinology and Metabolism, 2009
Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas.
Amar L et al.
The Journal of Clinical Endocrinology and Metabolism, 2007
The occurrence of SDHB gene mutations in pheochromocytoma.
Van Nederveen FH et al.
Annals of the New York Academy of Sciences, 2006
Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes.
Benn DE et al.
The Journal of Clinical Endocrinology and Metabolism, 2006
A thyroid nodule revealing a paraganglioma in a patient with a new germline mutation in the succinate dehydrogenase B gene.
Zantour B et al.
European Journal of Endocrinology, 2004